N@N

Carter Gould Upgraded (BIIB) to Strong Buy on, Jan 31st, 2018

Carter Gould of UBS, Upgraded "Biogen Inc." (BIIB) to Strong Buy on, Jan 31st, 2018.

Carter has made no other calls on BIIB in the last 4 months.

There are 12 other peers that have a rating on BIIB. Out of the 12 peers that are also analyzing BIIB, 2 agree with Carter's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $350 on, Wednesday, January 24th, 2018
• Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold on, Monday, October 23rd, 2017

These are the ratings of the 10 analyists that currently disagree with Carter

---

• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $363 on, Friday, January 26th, 2018
• Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Friday, January 26th, 2018
• Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $386 on, Monday, November 6th, 2017
• Jeffrey Silber of "BMO Capital" Upgraded from Hold to Buy on, Wednesday, October 25th, 2017
• Adnan Butt of "Guggenheim" Initiated at Strong Buy and Held Target at $402 on, Tuesday, October 24th, 2017
• Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $390 on, Monday, October 23rd, 2017
• Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
• Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017

Contributing Sources

---